• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by FS Development Corp. II

    12/13/21 11:36:19 AM ET
    $FSII
    Finance
    Get the next $FSII alert in real time by email
    SC 13G 1 fsii13gnov21.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. )

     

    FS Development Corp. II

    (Name of Issuer)

     

    COMMON STOCK

    (Title of Class of Securities)

     

    30318F100

    (CUSIP NUMBER)

     

    November 30, 2021

    (Date of Event which Requires Filing of Statement)

     

    Check the appropriate box to designate the Rule pursuant to which this

    Schedule is filed:

    [x] Rule 13d - 1(b)

    Rule 13d - 1(c)

    Rule 13d - 1(d)

     

    1. Name of Reporting Person

    T. ROWE PRICE ASSOCIATES, INC.

    52-0556948

     

    2. Check the Appropriate Box if a Member of a Group

    NOT APPLICABLE

     

    3. SEC Use Only

     

    4. Citizenship or Place of Organization

    Maryland

     

    Number of Shares Beneficially Owned by Each Reporting Person With

     

    5. Sole Voting Power* 301,585

     

    6. Shared Voting Power* 0

     

    7. Sole Dispositive Power* 2,542,852

     

    8. Shared Dispositive Power 0

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person

    2,542,852

     

    10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

    NOT APPLICABLE

     

    11. Percent of Class Represented by Amount in Row 9

    12.2%

     

    12. Type of Reporting Person

    IA

     

    *Any shares reported in Items 5 and 6 are also reported in Item 7.

     

    1. Name of Reporting Person

    T. ROWE PRICE NEW HORIZONS FUND, INC.

    52-0791372

     

    2. Check the Appropriate Box if a Member of a Group

    NOT APPLICABLE

     

    3. SEC Use Only

     

    4. Citizenship or Place of Organization

    Maryland

     

    Number of Shares Beneficially Owned by Each Reporting Person With

     

    5. Sole Voting Power* 1,237,491

     

    6. Shared Voting Power* 0

     

    7. Sole Dispositive Power* 0

     

    8. Shared Dispositive Power 0

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person

    1,237,491

     

    10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

    NOT APPLICABLE

     

    11. Percent of Class Represented by Amount in Row 9

    5.9%

     

    12. Type of Reporting Person

    IV

     

    *Any shares reported in Items 5 and 6 are also reported in Item 7.

     

    Item 1(a) Name of Issuer:

    FS Development Corp. II

     

    Item 1(b) Address of Issuer's Principal Executive Offices:

    600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO, CA 94111

     

    Item 2(a) Name of Person(s) Filing:

    (1) T. ROWE PRICE ASSOCIATES, INC. ("Price Associates")

    (2) T. ROWE PRICE NEW HORIZONS FUND, INC.

     

    X Attached as Exhibit A is a copy of an agreement between the Persons Filing

    (as specified hereinabove) that this Schedule 13G is being filed on behalf

    of each of them.

     

     

    Item 2(b) Address of Principal Business Office:

    100 E. Pratt Street, Baltimore, MD 21202

     

    Item 2(c) Citizenship or Place of Organization:

    (1) Maryland

    (2) Maryland

     

    Item 2(d) Title of Class of Securities: COMMON STOCK

     

    Item 2(e) Cusip Number: 30318F100

     

    Item 3: The person filing this Schedule 13G is an:

    X Investment Adviser registered under Section 203 of the Investment

    Advisers Act of 1940

    X Investment Company registered under Section 8 of the Investment

    Company Act of 1940

     

    Item 4: Reference is made to Items 5-11 on the preceding pages of this

    Schedule 13G.

     

    Item 5: Ownership of Five Percent or Less of a Class

    Not Applicable

     

    Item 6: Ownership of More than Five Percent on Behalf of Another Person

     

    (1) Price Associates does not serve as custodian of the assets of any of

    its clients; accordingly, in each instance only the client or the

    client's custodian or trustee bank has the right to receive dividends

    paid with respect to, and proceeds from the sale of, such securities.

     

    The ultimate power to direct the receipt of dividends paid with

    respect to, and the proceeds from the sale of, such securities, is

    vested in the individual and institutional clients which Price

    Associates serves as investment adviser. Any and all discretionary

    authority which has been delegated to Price Associates may be revoked

    in whole or in part at any time.

     

    Except as may be indicated if this is a joint filing with one of the

    registered investment companies sponsored by Price Associates which it

    also serves as investment adviser ("T. Rowe Price Funds"), not more

    than 5% of the class of such securities is owned by any one client

    subject to the investment advice of Price Associates.

     

    (2) With respect to securities owned by any one of the T. Rowe Price

    Funds, only the custodian for each of such Funds, has the right to

    receive dividends paid with respect to, and proceeds from the sale of,

    such securities. No other person is known to have such right, except

    that the shareholders of each such Fund participate proportionately

    in any dividends and distributions so paid.

     

    Item 7: Identification and Classification of the Subsidiary Which Acquired the

    Security Being Reported on By the Parent Holding Company.

    Not Applicable

     

    Item 8: Identification and Classification of Members of the Group

    Not Applicable

     

    Item 9: Notice of Dissolution of Group

    Not Applicable

     

    Item 10: Certification

    By signing below I certify that, to the best of my knowledge and

    belief, the securities referred to above were acquired in the

    ordinary course of business and were not acquired and are not

    held for the purpose of or with the effect of changing or

    influencing the control of the issuer of the securities and were

    not acquired and are not held in connection with or as a participant

    in any transaction having that purpose or effect. T. Rowe Price

    Associates, Inc. hereby declares and affirms that the filing

    of Schedule 13G shall not be construed as an admission that Price

    Associates is the beneficial owner of the securities referred to,

    which beneficial ownership is expressly denied.

     

    Signature.

     

    After reasonable inquiry and to the best of my knowledge and belief,

    I certify that the information set forth in this statement is true,

    complete and correct.

     

    T. ROWE PRICE ASSOCIATES, INC.

    Date: December 10, 2021

    Signature: /s/ David Oestreicher

    Name & Title: David Oestreicher, Executive Vice President

     

    T. ROWE PRICE NEW HORIZONS FUND, INC.

    Date: December 10, 2021

    Signature: /s/ David Oestreicher

    Name & Title: David Oestreicher, Executive Vice President

     

    11/30/2021

     

    EXHIBIT A

    AGREEMENT

    JOINT FILING OF SCHEDULE 13G

     

    Price Associates, Inc. (an investment adviser registered under the Investment

    Advisers Act of 1940), and

    T. ROWE PRICE NEW HORIZONS FUND, INC.,

    all of which are Maryland corporations, hereby agree to file jointly the

    statement on Schedule 13G to which this Agreement is attached, and any

    amendments thereto which may be deemed necessary, pursuant to Regulation 13D-G

    under the Securities Exchange Act of 1934.

     

    It is understood and agreed that each of the parties hereto is responsible for

    the timely filing of such statement and any amendments thereto, and for the

    completeness and accuracy of the information concerning such party contained

    therein, but such party is not responsible for the completeness or accuracy of

    information concerning the other party unless such party knows or has reason to

    believe that such information is inaccurate.

     

    It is understood and agreed that a copy of this Agreement shall be attached as

    an exhibit to the statement on Schedule 13G, and any amendments hereto, filed

    on behalf of each of the parties hereto.

     

     

     

     

     

    T. ROWE PRICE ASSOCIATES, INC.

    Date: December 10, 2021

    Signature: /s/ David Oestreicher

    Name & Title: David Oestreicher, Executive Vice President

     

    T. ROWE PRICE NEW HORIZONS FUND, INC.

    Date: December 10, 2021

    Signature: /s/ David Oestreicher

    Name & Title: David Oestreicher, Executive Vice President

    Get the next $FSII alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FSII

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FSII
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Tananbaum James B. converted options into 4,941,250 shares (Amendment)

    4/A - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)

    12/30/21 4:30:19 PM ET
    $FSII
    Finance

    SEC Form 4: Pakianathan Deepika converted options into 30,000 shares (Amendment)

    4/A - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)

    12/30/21 4:00:26 PM ET
    $FSII
    Finance

    SEC Form 4: Hughes Owen converted options into 30,000 shares (Amendment)

    4/A - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)

    12/30/21 4:00:23 PM ET
    $FSII
    Finance

    $FSII
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pardes Biosciences Debuts as a Publicly Traded Company Focused on Oral Antiviral Therapies to Potentially Treat and Prevent COVID-19

    Ongoing Phase I trial shows potential for stand-alone, unboosted agent against COVID-19 Gross proceeds made available to Pardes Biosciences from transaction totaled approximately $274 million, combining approximately $199 million of funds held in FS Development Corp. II's trust account and concurrent PIPE financing of $75 million Business combination transaction with FS Development Corp. II, a special purpose acquisition company sponsored by Foresite Capital, completed on December 23, 2021 Combined company renamed Pardes Biosciences, Inc. Common stock commences trading today under ticker symbol "PRDS" on the Nasdaq Global Market CARLSBAD, Calif. and BERKELEY, Calif., Dec. 27, 2021 (G

    12/27/21 7:00:00 AM ET
    $FSII
    Finance

    FSII and Pardes Biosciences Move Towards Merger With the Goal of Tackling COVID-19 via an Oral Antiviral for Treatment and Prevention of SARS-CoV-2 Infections

    Proposed merger heads to shareholder vote on December 23rd as ongoing Phase I trial shows potential for unboosted oral regimen In advance of the shareholder vote for the business combination between FS Development Corp. II (NASDAQ:FSII) and Pardes Biosciences, Inc. ("Pardes"), the CEOs of both companies are sharing their thoughts on the COVID-19 public health emergency and how they expect the combined company to play an important role in addressing one of the biggest health crises of our time. "We believe that direct-acting antivirals against coronavirus that are taken orally – such as our PBI-0451 – will become increasingly important in a world where SARS-CoV-2 may become endemic. This e

    12/21/21 7:00:00 AM ET
    $FSII
    Finance

    FS Development Corp. II Announces Effectiveness of Registration Statement for Proposed Business Combination with Pardes Special Meeting Scheduled for December 23, 2021

    FS Development Corp. II, a Delaware corporation (the "Company") (NASDAQ:FSII), announced today that its registration statement on Form S-4 (File No. 333-258442) (as amended, the "Registration Statement"), relating to the previously announced business combination (the "Business Combination") with Pardes Biosciences, Inc. ("Pardes"), has been declared effective by the U.S. Securities and Exchange Commission ("SEC") and that it has commenced mailing the definitive proxy statement/prospectus relating to the Special Meeting (the "Special Meeting") of the Company's stockholders to be held on December 23, 2021 in connection with the Business Combination. The proxy statement/prospectus is being mai

    12/1/21 11:38:00 AM ET
    $FSII
    Finance

    $FSII
    SEC Filings

    View All

    FS Development Corp. II filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PARDES BIOSCIENCES, INC. (0001822711) (Filer)

    1/7/22 7:00:50 AM ET
    $FSII
    Finance

    FS Development Corp. II filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Material Modification to Rights of Security Holders, Changes in Registrant’s Certifying Accountant, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Change in Shell Company Status, Other Events

    8-K - PARDES BIOSCIENCES, INC. (0001822711) (Filer)

    12/30/21 4:55:34 PM ET
    $FSII
    Finance

    FS Development Corp. II filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PARDES BIOSCIENCES, INC. (0001822711) (Filer)

    12/27/21 7:09:01 AM ET
    $FSII
    Finance

    $FSII
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by FS Development Corp. II

    SC 13G - PARDES BIOSCIENCES, INC. (0001822711) (Subject)

    1/10/22 5:00:36 PM ET
    $FSII
    Finance

    SEC Form SC 13G/A filed by FS Development Corp. II (Amendment)

    SC 13G/A - PARDES BIOSCIENCES, INC. (0001822711) (Subject)

    1/10/22 2:12:29 PM ET
    $FSII
    Finance

    SEC Form SC 13D filed by FS Development Corp. II

    SC 13D - PARDES BIOSCIENCES, INC. (0001822711) (Subject)

    12/30/21 5:09:44 PM ET
    $FSII
    Finance